Samda Biolab reports 5.1% stake in Liminatus Pharma

Samda Biolab Co., Ltd. reported beneficial ownership of Common Stock of Liminatus Pharma, Inc..

Rhea-AI Filing Summary

Samda Biolab Co., Ltd. reported beneficial ownership of Common Stock of Liminatus Pharma, Inc.. Samda Biolab holds 3,426,548 shares of Common Stock, representing 5.1% of the class, based on 67,160,362 shares outstanding as of July 2, 2026.

Samda Biolab has sole voting and sole dispositive power over all 3,426,548 shares, with no shared voting or dispositive power reported.

Key Figures

Beneficially owned shares: 3,426,548 shares Percent of class: 5.1% Shares outstanding: 67,160,362 shares +2 more

5 metrics

Beneficially owned shares 3,426,548 shares Common Stock beneficially owned by Samda Biolab Co., Ltd.

Percent of class 5.1% Ownership percentage of Liminatus Pharma Common Stock held by Samda Biolab

Shares outstanding 67,160,362 shares Common Stock outstanding as of July 2, 2026, used for ownership calculation

Sole voting power 3,426,548 shares Shares over which Samda Biolab has sole power to vote or direct the vote

Sole dispositive power 3,426,548 shares Shares over which Samda Biolab has sole power to dispose or direct disposition

Key Terms

beneficially owned, Percent of class, sole voting power, dispositive power, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 3,426,548"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Percent of class financial

"(b) | Percent of class: 5.1%*"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

sole voting power financial

"Sole power to vote or to direct the vote: 3,426,548"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole power to dispose or to direct the disposition of: 3,426,548"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"form_type: "SCHEDULE 13G""

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Liminatus Pharma (LIMN) does Samda Biolab own?

Samda Biolab Co., Ltd. beneficially owns 5.1% of Liminatus Pharma’s Common Stock. This percentage is based on 67,160,362 shares of Common Stock outstanding as of July 2, 2026.

How many Liminatus Pharma (LIMN) shares are beneficially owned by Samda Biolab?

Samda Biolab Co., Ltd. beneficially owns 3,426,548 shares of Liminatus Pharma Common Stock. These shares are held with sole voting and sole dispositive power and no shared authority reported.

What is the total number of Liminatus Pharma (LIMN) shares outstanding used for the 5.1% ownership calculation?

The 5.1% ownership figure is calculated using 67,160,362 shares of Liminatus Pharma Common Stock outstanding as of July 2, 2026, as specified in the ownership calculation note.

Does Samda Biolab share voting power over its Liminatus Pharma (LIMN) shares?

No. Samda Biolab reports 3,426,548 shares with sole voting power and 0 shares with shared voting power. It likewise reports sole, not shared, dispositive power over these shares.

Where is Samda Biolab, the 5.1% Liminatus Pharma (LIMN) holder, organized and located?

Samda Biolab Co., Ltd. is organized in the Republic of South Korea, with a principal office at #801 Factory building, 138, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea 10442.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/22/2026 - 05:07 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Liminatus Pharma, Inc.

(Name of Issuer)

Common Stock , par value $0.0001 per share

(Title of Class of Securities)

53271X108

(CUSIP Number)

07/02/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 53271X108

1

Names of Reporting Persons

Samda Biolab Co., Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

KOREA, REPUBLIC OF

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,426,548.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,426,548.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,426,548.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: For Row 11, percentage is calculated based on 67,160,362 shares of Common Stock outstanding on July 2, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Liminatus Pharma, Inc.
(b)	Address of issuer's principal executive offices: 2251 Stern Goodman Street, Suite E, Fullerton, CA 92833
Item 2.
(a)	Name of person filing: Samda Biolab Co., Ltd.
(b)	Address or principal business office or, if none, residence: #801 Factory building, 138, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea 10442
(c)	Citizenship: Republic of South Korea
(d)	Title of class of securities: Common Stock , par value $0.0001 per share
(e)	CUSIP Number(s): 53271X108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,426,548
(b)	Percent of class: 5.1%* * Percentage is calculated based on 67,160,362 shares of Common Stock outstanding on July 2, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,426,548
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,426,548
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Samda Biolab Co., Ltd.

Signature:	/s/ Beom K. Choi
Name/Title:	Beom K. Choi, Chief Executive Officer
Date:	07/22/2026